Results 51 to 60 of about 7,693 (199)
HemaSphere, 2022 In adult patients, the treatment outcome of acute lymphoblastic leukemia (ALL) remains suboptimal. Here, we used an ex vivo drug testing platform and comprehensive molecular profiling to discover new drug candidates for B-ALL.
Helena Hohtari +11 more
doaj +1 more source
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax [PDF]
Molecular Pharmacology, 2019 Developing small molecules that indirectly regulate Mcl-1 function has attracted a lot of attention in recent years. Here, we report the discovery of an aminopyrazole, 2-([1,1'-biphenyl]-4-yl)-N-(5-cyclobutyl-1H-pyrazol-3-yl)acetamide (analog 24), which selectively inhibited cyclin-dependent kinase (CDK) 5 over CDK2 in cancer cell lines.
Kour, Smit +12 more
openaire +2 more sources
Breast Cancer Research, 2020 Background Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to evaluate the
Jason J. Zoeller +13 more
doaj +1 more source
Targeting the Bcl-2 Family in B Cell Lymphoma
Frontiers in Oncology, 2019 Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells.
Clare M. Adams +3 more
doaj +1 more source
Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
Cell Death Discovery, 2023 Uveal melanoma (UM) has a high risk to progress to metastatic disease with a median survival of 3.9 months after metastases detection, as metastatic UM responds poorly to conventional and targeted chemotherapy and is largely refractory to immunotherapy ...
Arwin Groenewoud +12 more
doaj +1 more source
Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models [PDF]
Clinical Cancer Research, 2011 Abstract Purpose: To explore the potential of navitoclax in combination with taxane-based chemotherapy in the treatment of non–small cell lung cancer (NSCLC) by defining mechanism of synergy and identifying correlative biomarkers. Experimental Design: We treated a panel of NSCLC lines with a dose matrix of paclitaxel
Nguyen, Tan +8 more
openaire +2 more sources
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis [PDF]
, 2017 The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies.
Butterworth, Michael +6 more
core +5 more sources
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. [PDF]
, 2012 BH3 mimetics such as ABT-737 and navitoclax bind to the BCL-2 family of proteins and induce apoptosis through the intrinsic apoptosis pathway. There is considerable variability in the sensitivity of different cells to these drugs.
Redman, CW, Richardson, A, Stamelos, VA
core +2 more sources
Modulation of protein-protein interactions for the development of novel therapeutics [PDF]
, 2016 Protein-protein interactions (PPIs) underlie most biological processes. An increasing interest to investigate the unexplored potential of PPIs in drug discovery is driven by the need to find novel therapeutic targets for a whole range of diseases with a ...
De Bosscher, Karolien +4 more
core +2 more sources
Identification of small-molecule inhibitors of the antiapoptotic protein myeloid cell leukaemia-1 (Mcl-1) [PDF]
, 2016 Protein–protein interactions (PPIs) control many cellular processes in cancer and tumour growth. Of significant interest is the role PPIs play in regulating apoptosis.
Adams +38 more
core +1 more source